What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial).

December 8, 2025BloodOpen Access

A prospecitive, multicenter study of chidamide in adult patients with refractory primary immune thrombocytopenia

View Full Paper

Ask AI

Bookmark

Authors

Randomized clinical trial showed that chidamide improved platelet count in patients with refractory ITP, indicating its potential therapeutic role.

Chidamide improved overall response rates in patients with refractory immune thrombocytopenia, leading to better health outcomes.
At week 12, 43.3% of patients in the 5 mg group achieved an overall response, significantly higher than the 2.5 mg group.
Clinical trial revealed that the 5 mg dose yielded longer duration of response and better patient quality of life.
Chidamide was well tolerated, with common adverse events including fatigue and elevated liver enzymes.

Ruirong Xu (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Randomized clinical trial showed that chidamide improved platelet count in patients with refractory ITP, indicating its potential therapeutic role.

Chidamide improved overall response rates in patients with refractory immune thrombocytopenia, leading to better health outcomes.
At week 12, 43.3% of patients in the 5 mg group achieved an overall response, significantly higher than the 2.5 mg group.
Clinical trial revealed that the 5 mg dose yielded longer duration of response and better patient quality of life.
Chidamide was well tolerated, with common adverse events including fatigue and elevated liver enzymes.

Ruirong Xu (2025) studied this question.

View Full Paper

Ask AI

Bookmark